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Ian M C DixonAbstract
We are pleased to introduce a new thematic series dealing with cardiac fibrosis and its association with
cardiovascular diseases. A wide variety of cardiovascular diseases are associated with cardiac fibrosis, which is now
widely recognized to be not a secondary, but rather a primary contributor to cardiac dysfunction. The purpose of
the current series of papers and reviews is to provide the reader with an up-to-date synopsis of the very latest
research results and hypotheses that impact on cardiac fibrosis and disease.
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ance” and is the title of the popular environmentalist
movie shot nearly 2 decades ago. The film contrasts
speeded-up images of American desert landscapes and
life without man to smokestacks and expressways and
an endless flow of humanity through the streets of any
large city. The movie is beautifully created and sup-
ported by technical excellence in imagery and sound, to
the point where one might make an honest mistake and
misinterpret the main message, as indeed some of the
images that were intended to repel to the viewer are
appealing themselves. Using this representation of
despoiled environment as an allegory of the presence of
fibroblasts and their role in pathogenesis of fibrotic heart
disease, the connection may be more easily discerned. In
this regard, our laboratory has used an in vitro scratch
assay and has compiled data depicting a greatly acceler-
ated account of a 16-h duration showing migration of
activated myofibroblasts (Additional file 1: Figure 1).
Others have aptly described this assay as a “heart attack
in a plate,” which is a convenient and inexpensive
method to assess myofibroblast migration from the
highly confluent area of cells into the denuded region
[1]. In this figure, virtually all of the cells in the area
photographed are myofibroblasts. Studying the film loop
of myofibroblasts reveals a number of interestingCorrespondence: idixon@sbrc.ca
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reproduction in any medium, provided the orphenomena. Cells in proximity to the denuded region
become suddenly motile, and they reorient, divide, and
migrate at greatly accelerated velocity vs. their relatively
quiescent neighbors. While their movement from an
area of relative confluence to the denuded area is fascin-
ating in itself, it is likely a reasonably accurate reflection
of their motility in vivo, e.g., in ongoing wound healing
of necrosed muscle in post-MI heart and/or stroma. We
have previously shown that cardiac myofibroblasts are
hypersynthetic and are key players in the development
of cardiac fibrosis. As such, they are included within the
focus of a new thematic series of reviews (Cardiovascular
Diseases) to provide information about some of the re-
cent developments in our understanding of the patho-
genesis of cardiac fibrosis, to be published during the
coming year in Fibrogenesis and Tissue Repair.
What is the difference between healthy cardiac fibro-
blast function and that of cardiac myofibroblasts? Matrix
components of the healthy heart are produced by inter-
stitial cardiac fibroblasts [2]. These cells maintain a rela-
tively slow turnover of fibrillar collagens [3] in normal
conditions, but may respond to both mechanical loading
[4] and TGF-β1 stimulation [5,6] by a switch to a myofi-
broblastic phenotype wherein they express α-smooth
muscle actin (αSMA) [7], synonymous with increased
contractile force [8]. αSMA expression is increased in
myofibroblasts in fibrotic hearts subjected to pressure or
volume overload or in the infarct scar of post-MI hearts
[3]. Causal factors in this conversion are compressibility
of the substrate when ventricular fibroblasts are platedis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Enhanced contractility that attends this protein’s expres-
sion is believed to be important in allowing these cells to
contract while bound to matrix collagens and other pro-
teins, thereby allowing for physical remodeling of the
matrix itself [11]. Thus myofibroblasts are the primary
mediators of wound healing in the damaged ventricle
and we have previously demonstrated that they are the
dominant cell type in the infarct scar [12]. Myofibro-
blasts migrate to the infarct zone, restoring cellularity
[13]. Their contraction confers matrix remodeling by
imparting tensile force to the matrix, opposes retractile
force, promotes scar contraction, activates latent TGF-β1,
and reorients collagen fibrils [4,14–16]. Investigation of
these cells in hypertrophied hearts is clinically relevant
as they contribute to wound healing, matrix remodeling,
and eventual cardiac fibrosis through the elevated pro-
duction of fibrillar and non-fibrillar collagens [17,18].
The new thematic series to be published in this jour-
nal will touch upon topics not commonly associated
with “textbook” knowledge of cardiac fibroblasts.
Included in the range of topics in which we will be
accepting submissions of novel research papers and re-
view articles are: (1) the role of fibroblast and myofi-
broblast autophagy in the regulation of cellular
function, (2) the relative contribution of migratory stem
cells in populating the heart with myofibroblasts vs. en-
dogenous conversion of fibroblasts to myofibroblasts,
(3) the roles of pericytes, epithelial-to-mesenchymal
transition (EMT), endothelial-to-mesenchymal transi-
tion (EndMT), and fibrocytes in influencing cardiac
extracellular matrix remodeling in heart disease, (4)
microRNA influence on myofibroblast function, (5)
novel signaling pathways and mechanotransduction in
the regulation of myofibroblast function, (6) exploration
of the role of non-collagenous proteins in the cardiac
extracellular matrix, (7) developments in MMP and
TIMP biology in the heart, (8) valvular interstitial cells
and valve disease, and finally, (9) novel aspects of myo-
fibroblast biology. As these areas represent novel con-
cepts in heart disease and cardiac fibrosis and could be
described as areas less well-covered in the literature,
they are to be our current focus.
Why should clinicians or basic scientists care about
these new developments? Part of the answer lies in the
novel suggestion that cardiac fibroblasts and myofibro-
blasts are unique cells, e.g., distinguished by their rela-
tive specific phenotype from other fibroblastic cells.
While it is well-known that the structural scaffold that
exists between myocytes in the heart is composed of
extracellular matrix (matrix) and mesenchymal cells and
that this matrix provides an exceptionally strong means
to tether and coordinate force generated via myocyte
contraction, little is known of their regulation. Theprincipal stromal cell type is fibroblasts, but this desig-
nation belies their diversity and topographic differenti-
ation from organ to organ including the heart [19].
Thus, the term “fibroblasts” designates a highly hetero-
geneous group that exhibits distinct differentiated phe-
notypes in different tissues [19]. The implications of
these fundamental differences are unclear. Further, the
study of fibroblast and myofibroblast biology in specific
organs is an important but relatively understudied area,
especially in cardiovascular disease with attendant car-
diac fibrosis. Recent novel data indicate that ventricular
fibroblast activation and cardiac fibrosis are primary
events in ventricular remodeling, rather than a second-
ary response to cardiomyocyte injury [20]. Thus the
traditional role of cardiac fibrosis as a secondary disease
modifier has, for the first time, been called into question
[20], and the need to investigate factors that regulate
cardiac myofibroblasts in various types of cardiovascular
disease is apparent. For these reasons we have sought to
publish a series of papers that will highlight the molecu-
lar and biochemical properties of these specific cells, and
of their functioning in disease. Finally, the field of car-
diac fibrosis has experienced a burgeoning level of inter-
est and participation in investigations during the past 5
years, and this series will take advantage of this to show-
case the thoughts of what some of the best minds in area
are thinking.
Additional file
Additional file 1: Figure 1. Scratch Assay of Cardiac Myofibroblasts.
Time-lapse movie (10 s) of primary rat cardiac myofibroblasts in first
passage compressed form 16 hours of incubation in a Zeiss live-cell
incubation in a Zeiss live-cel l incubation chamber. Cells are cultured in
DMEM/F 12 in the presence of fetal bovine serum. These cells express
significant levels of a SMA and ED-A fibronectin proteins that designate
them as myofibroblasts.
Competing interests
The authors declare that they have no competing interests.
Acknowledgment
This work is supported by a grant-in-aid from the Heart and Stroke
Foundation of Manitoba, an operating grant from the Canadian Institutes of
Health Research, and the St. Boniface Hospital Research Foundation.
Received: 26 July 2012 Accepted: 30 July 2012
Published: 3 September 2012
References
1. Liang CC, Park AY, Guan JL: In vitro scratch assay: a convenient and
inexpensive method for analysis of cell migration in vitro.
Nat Protoc 2007, 2:329–333.
2. Eghbali M, Czaja MJ, Zeydel M, Weiner FR, Zern MA, Seifter S, Blumenfeld OO:
Collagen chain mRNAs in isolated heart cells from young and adult rats.
J Mol Cell Cardiol 1988, 20:267–276.
3. Weber KT: Fibrosis, a common pathway to organ failure: angiotensin II
and tissue repair. Semin Nephrol 1997, 17:467–491.
4. Wang J, Chen H, Seth A, McCulloch CA: Mechanical force regulation of
myofibroblast differentiation in cardiac fibroblasts. Am J Physiol Heart Circ
Physiol 2003, 285:H1871–H1881.
Dixon Fibrogenesis & Tissue Repair 2012, 5:14 Page 3 of 3
http://www.fibrogenesis.com/content/5/1/145. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth
factor-beta 1 induces alpha-smooth muscle actin expression in
granulation tissue myofibroblasts and in quiescent and growing
cultured fibroblasts. J Cell Biol 1993, 122:103–111.
6. Petrov VV, Fagard RH, Lijnen PJ: Stimulation of collagen production by
transforming growth factor-beta1 during differentiation of cardiac
fibroblasts to myofibroblasts. Hypertension 2002, 39:258–263.
7. Leslie KO, Taatjes DJ, Schwarz J, von Turkovich M, Low RB: Cardiac
myofibroblasts express alpha smooth muscle actin during right
ventricular pressure overload in the rabbit. Am J Pathol 1991,
139:207–216.
8. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C: Alpha-smooth
muscle actin expression upregulates fibroblast contractile activity.
Mol Biol Cell 2001, 12:2730–2741.
9. Masur SK, Dewal HS, Dinh TT, Erenburg I, Petridou S: Myofibroblasts
differentiate from fibroblasts when plated at low density. Proc Natl Acad
Sci USA 1996, 93:4219–4223.
10. Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang XF,
Frangogiannis NG: Essential Role of Smad3 in Infarct Healing and in the
Pathogenesis of Cardiac Remodeling. Circulation 2007, 116:2127–2138.
11. Arora PD, McCulloch CA: Dependence of collagen remodelling on alpha-
smooth muscle actin expression by fibroblasts. J Cell Physiol 1994,
159:161–175.
12. Peterson DJ, Ju H, Hao J, Panagia M, Chapman DC, Dixon IM: Expression of
Gi-2 alpha and Gs alpha in myofibroblasts localized to the infarct scar in
heart failure due to myocardial infarction. Cardiovasc Res 1999,
41:575–585.
13. Norman D: An exploration of two opposing theories of wound
contraction. J Wound Care 2004, 13:138–140.
14. Arany PR, Flanders KC, Kobayashi T, Kuo CK, Stuelten C, Desai KV, Tuan R,
Rennard SI, Roberts AB: Smad3 deficiency alters key structural elements
of the extracellular matrix and mechanotransduction of wound closure.
Proc Natl Acad Sci USA 2006, 103:9250–9255.
15. Lijnen P, Petrov V, Fagard R: Transforming growth factor-beta 1-mediated
collagen gel contraction by cardiac fibroblasts. J Renin Angiotensin
Aldosterone Syst 2003, 4:113–118.
16. Wipff PJ, Rifkin DB, Meister JJ, Hinz B: Myofibroblast contraction activates
latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007,
179:1311–1323.
17. Cleutjens JP, Verluyten MJ, Smits JF, Daemen MJ: Collagen remodeling
after myocardial infarction in the rat heart. Am J Pathol 1995,
147:325–338.
18. Shamhart PE, Meszaros JG: Non-fibrillar collagens: Key mediators of post-
infarction cardiac remodeling? J Mol Cell Cardiol 2009, .
19. Chang HY, Chi JT, Dudoit S, Bondre C, van de RM, Botstein D, Brown PO:
Diversity, topographic differentiation, and positional memory in human
fibroblasts. Proc Natl Acad Sci USA 2002, 99:12877–12882.
20. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S,
Rottbauer W, Frantz S, et al: MicroRNA-21 contributes to myocardial
disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008,
456:980–984.
doi:10.1186/1755-1536-5-14
Cite this article as: Dixon: Cardiac myofibroblasts: cells out of balance.
A new thematic series. Fibrogenesis & Tissue Repair 2012 5:14.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
